Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

Admin—April 28, 20250

The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) is seen on the facade of the company’s Munich headquarters on August 29, 2024 in Munich (Bavaria).

Matthias Balk | Picture Alliance | Getty Images

Bristol Myers Squibb‘s earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now.

Corporate sponsors are backing away from LGBTQ+ Pride organizations

German fiscal boost won’t outweigh tariff drag for euro zone, IMF’s Europe head says

Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

OpenAI hits $10 billion in annual recurring revenue fueled by ChatGPT growth

These are the 4 big things we’re watching in the stock market in the week ahead

MongoDB plummets nearly 27% for worst day ever as weak outlook overshadows strong quarterly results

Cracker Barrel stock falls as company reports mixed earnings after rebrand controversy

Nike tops earnings estimates but shares fall as China sales plunge, tariffs hit profits

Salesforce’s raised guidance lifts the stock but doesn’t change our rating

Oracle plummets 11% on weak revenue, pushing down AI stocks like Nvidia and CoreWeave

Visa says new AI shopping tool has helped customers with hundreds of transactions

Trust these numbers? Economists see a lot of flaws in delayed CPI report showing downward inflation

Nike tops earnings estimates but shares fall as China sales plunge, tariffs hit profits

American Airlines no longer lets basic economy flyers earn miles

Billionaire fund manager Ron Baron praises beaten-up financial stock whose new CEO he compares to Jamie Dimon

Watch Fed Governor Christopher Waller speak on interest rates and the race to succeed Powell